Identification of Laboratory Biomarkers for Early Detection and Clinical Management of Post-Acute Syndrome Among Survivors of the 2013–2016 West Africa Ebola Outbreak in Sierra Leone
Open Access
- 1 February 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 14, 119-132
Abstract
Background: The clinical management of persistent medical conditions affecting Ebola survivors, generally described as a post-Ebola syndrome, remains a public health concern. We aimed to analyze Ebola survivors’ laboratory biomarkers as compared to their non-infected household relatives to identify biomarkers that could guide the identification of survivors at increased risk of developing severe at odds with the non-severe post-Ebola syndrome. Materials and Methods: Data were extracted from medical records of the Ebola survivors clinic, and we included only Ebola survivor’s parameters recorded during the first baseline follow-up visit 2 weeks interval after their second negative PCR result. Moreover, household non-infected family contacts of survivors visiting the clinic during the same period were recruited as community control. Results: The mean age of survivors was 32.65 (IQR: 15.5, 38.25) years, and Ebola IgG immunoglobulin was detected in all, thus confirming their status. The statistical significance (all p < 0.05) observed in monocyte percentage (MONO%), cluster of differentiation 4 percentage (CD4%), alanine aminotransferase (ALT), creatinine (CREA), and creatinine kinase (C-kinase) proved to be clinically significant as compared to the household relatives’ group. Interestingly, the linear regression analysis indicated that the duration at ETU was negatively associated with lymphocyte percentage with a 5% lymphocyte decrease per day spent at ETU. Finally, there was a significant (p < 0.05) association between hematological (Hb, PCV, MCV, MCH), biochemical (ALT, CREA, C-kinase, T-cholesterol, triglycerides) parameters and the risk of developing severe complications. Conclusion: We recommend clinicians closely monitor Hb, PCV, MCV, MCH, ALT, CREA, C-kinase, T-cholesterol, triglycerides and lymphocytes as clinically relevant laboratory biomarkers to identify survivors at higher risk of developing severe post-acute syndrome upon discharge from Ebola treatment unit including headache, abdominal pain, chest pain, ocular complication, arthralgia, hearing difficulty and erectile dysfunction which can impact health-related quality of life among Ebola survivors.Keywords
This publication has 8 references indexed in Scilit:
- Mobile health clinic for the medical management of clinical sequelae experienced by survivors of the 2013–2016 Ebola virus disease outbreak in Sierra Leone, West AfricaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Post-Ebola Syndrome, Sierra LeoneEmerging Infectious Diseases, 2016
- Ebola Virus Disease Complications as Experienced by Survivors in Sierra LeoneClinical Infectious Diseases, 2016
- Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral FluidOpen Forum Infectious Diseases, 2016
- Clinical Manifestations and Laboratory Diagnosis of Ebola Virus Infection2016
- Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort studyThe Lancet Infectious Diseases, 2015
- Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort studyThe Lancet Infectious Diseases, 2015
- Clinical Management of Filovirus-Infected PatientsViruses, 2012